Oncology

pipeline pipes RD research
Biotech

Cullinan puts kibosh on 2 cancer assets amid autoimmune refocus

The move balances the number of candidates in Cullinan’s pipeline, which now encompasses four named assets across autoimmune and cancer indications.
Fraiser Kansteiner Nov 6, 2025 1:26pm
Novo Nordisk

Novo drops oncology ambitions, early-stage MASH prospects

Nov 5, 2025 7:21am
GSK ESMO

GSK loses hope for CD226 cancer therapies, dropping ph. 2 assets

Oct 29, 2025 6:29am
graphic of a larger shark chomping up a smaller one

Cardiometabolic field drives M&A while cancer deals drop: report

Oct 27, 2025 2:39pm
Illustration connected puzzle pieces with the acronym MA

Ipsen inks €1B buyout of French biotech ImCheck

Oct 22, 2025 10:33am
antibody antibody-drug conjugate antibody drug conjugate ADC

Boehringer digs in on ADCs with $991M AimedBio licensing accord

Oct 15, 2025 10:05am
More News

Tubulis touts $361M series C as next-gen ADC data drop nears

Oct 15, 2025 5:01am

Turbine looks to turbocharge AstraZeneca's ADC discovery

Oct 9, 2025 6:00am

3 scientists win Nobel Prize for discovery of regulatory T cells

Oct 6, 2025 7:03am

White House pledges $100M to AI pediatric cancer project

Oct 1, 2025 11:06am